90Y-labeled monoclonal antibodies for cancer therapy

Int J Rad Appl Instrum B. 1986;13(4):453-6. doi: 10.1016/0883-2897(86)90024-3.


Monoclonal antibody 17-1A, which has specificity for colorectal carcinoma, was labeled with 90Y (10-20% radiolabeling yield). Tissue distribution studies in tumor-bearing nude mice were carried out. 90Y-labeled 17-1A showed good uptake in the SW 948 colon carcinoma cell line. However, 90Y-labeled A5C3, a monoclonal antihepatitis virus antibody studied as a control, showed similar uptake in this tumor. Neither antibody was taken up well by a WM-9 melanoma. It is believed that the loss of specificity observed is due to the low specific activity of the 90Y-labeled monoclonal antibody preparations used. This hypothesis is supported by radioimmunoassay data.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Cell Line
  • Colonic Neoplasms / radiotherapy*
  • Humans
  • Kinetics
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Neoplasms / diagnostic imaging*
  • Radionuclide Imaging
  • Tissue Distribution
  • Transplantation, Heterologous
  • Yttrium Radioisotopes / therapeutic use*


  • Antibodies, Monoclonal
  • Yttrium Radioisotopes